Artemis Investment Management LLP Boosts Stock Position in Tabula Rasa HealthCare Inc (NASDAQ:TRHC)

Artemis Investment Management LLP grew its stake in Tabula Rasa HealthCare Inc (NASDAQ:TRHC) by 26.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 280,133 shares of the company’s stock after purchasing an additional 58,930 shares during the period. Artemis Investment Management LLP owned approximately 1.26% of Tabula Rasa HealthCare worth $13,341,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of TRHC. Metropolitan Life Insurance Co NY lifted its holdings in Tabula Rasa HealthCare by 14.0% in the third quarter. Metropolitan Life Insurance Co NY now owns 6,578 shares of the company’s stock valued at $361,000 after acquiring an additional 808 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in Tabula Rasa HealthCare by 124.4% in the third quarter. Squarepoint Ops LLC now owns 53,407 shares of the company’s stock valued at $2,934,000 after acquiring an additional 29,609 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Tabula Rasa HealthCare by 892.4% in the third quarter. Point72 Asset Management L.P. now owns 188,231 shares of the company’s stock valued at $10,341,000 after acquiring an additional 169,263 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Tabula Rasa HealthCare by 1.2% in the third quarter. California State Teachers Retirement System now owns 30,396 shares of the company’s stock valued at $1,670,000 after acquiring an additional 363 shares during the last quarter. Finally, State Street Corp lifted its holdings in Tabula Rasa HealthCare by 2.7% in the third quarter. State Street Corp now owns 546,513 shares of the company’s stock valued at $30,025,000 after acquiring an additional 14,504 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

TRHC has been the topic of a number of recent analyst reports. BidaskClub cut Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a report on Monday, January 6th. Wells Fargo & Co decreased their price objective on Tabula Rasa HealthCare from $55.00 to $50.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 8th. Cantor Fitzgerald decreased their price objective on Tabula Rasa HealthCare from $99.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. ValuEngine cut Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 13th. Finally, Zacks Investment Research upgraded Tabula Rasa HealthCare from a “sell” rating to a “buy” rating and set a $54.00 price objective on the stock in a report on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $66.79.

NASDAQ:TRHC opened at $50.29 on Wednesday. The company has a quick ratio of 2.13, a current ratio of 2.22 and a debt-to-equity ratio of 1.32. The stock’s fifty day moving average is $45.28 and its two-hundred day moving average is $51.69. Tabula Rasa HealthCare Inc has a 52 week low of $37.41 and a 52 week high of $68.99. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of 147.91 and a beta of 1.51.

Tabula Rasa HealthCare (NASDAQ:TRHC) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Tabula Rasa HealthCare had a positive return on equity of 0.50% and a negative net margin of 13.46%. The company had revenue of $74.27 million for the quarter, compared to analysts’ expectations of $75.37 million. On average, sell-side analysts expect that Tabula Rasa HealthCare Inc will post -0.23 EPS for the current fiscal year.

In other Tabula Rasa HealthCare news, President Orsula V. Knowlton sold 628 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $47.75, for a total transaction of $29,987.00. Following the transaction, the president now directly owns 751,647 shares in the company, valued at $35,891,144.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Orsula V. Knowlton sold 8,000 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $50.28, for a total value of $402,240.00. Following the transaction, the president now owns 764,207 shares in the company, valued at $38,424,327.96. The disclosure for this sale can be found here. Insiders have sold 103,313 shares of company stock worth $4,759,106 over the last 90 days. 11.80% of the stock is owned by insiders.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Further Reading: Certificate of Deposit (CD) For Risk Adverse Investors?

Institutional Ownership by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply